SRTS Stock Overview
A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Sensus Healthcare, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.80 |
| 52 Week High | US$7.18 |
| 52 Week Low | US$1.79 |
| Beta | 1.06 |
| 11 Month Change | -14.45% |
| 3 Month Change | 10.90% |
| 1 Year Change | 121.37% |
| 33 Year Change | 46.46% |
| 5 Year Change | -3.49% |
| Change since IPO | -0.86% |
Recent News & Updates
Recent updates
Returns At Sensus Healthcare (NASDAQ:SRTS) Are On The Way Up
May 12
Potential Upside For Sensus Healthcare, Inc. (NASDAQ:SRTS) Not Without Risk
Apr 16Sensus Healthcare, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Feb 11There's Been No Shortage Of Growth Recently For Sensus Healthcare's (NASDAQ:SRTS) Returns On Capital
Oct 17Sensus Healthcare (NASDAQ:SRTS) Might Have The Makings Of A Multi-Bagger
Jul 04Lacklustre Performance Is Driving Sensus Healthcare, Inc.'s (NASDAQ:SRTS) 26% Price Drop
Mar 14Do Sensus Healthcare's (NASDAQ:SRTS) Earnings Warrant Your Attention?
Mar 06Sensus Healthcare (NASDAQ:SRTS) Could Become A Multi-Bagger
Oct 11Sensus Healthcare Q2 GAAP EPS, revenue beats
Aug 04Sensus Healthcare: A Buy In Honor Of Skin Cancer Awareness Month
May 21Analysts Just Made A Captivating Upgrade To Their Sensus Healthcare, Inc. (NASDAQ:SRTS) Forecasts
May 11Investors Will Want Sensus Healthcare's (NASDAQ:SRTS) Growth In ROCE To Persist
Apr 29Sensus Healthcare's (NASDAQ:SRTS) Earnings Are Of Questionable Quality
Apr 01Are Investors Undervaluing Sensus Healthcare, Inc. (NASDAQ:SRTS) By 31%?
Dec 17We Discuss Why Sensus Healthcare, Inc.'s (NASDAQ:SRTS) CEO Compensation May Be Closely Reviewed
May 30Shareholder Returns
| SRTS | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -4.8% | -0.3% | 1.6% |
| 1Y | 121.4% | 20.6% | 30.5% |
Return vs Industry: SRTS exceeded the US Medical Equipment industry which returned 20.8% over the past year.
Return vs Market: SRTS exceeded the US Market which returned 30.5% over the past year.
Price Volatility
| SRTS volatility | |
|---|---|
| SRTS Average Weekly Movement | 8.8% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SRTS has not had significant price volatility in the past 3 months.
Volatility Over Time: SRTS's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 35 | Joe Sardano | sensushealthcare.com |
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Sensus Healthcare, Inc. Fundamentals Summary
| SRTS fundamental statistics | |
|---|---|
| Market cap | US$95.06m |
| Earnings (TTM) | US$6.65m |
| Revenue (TTM) | US$36.37m |
14.3x
P/E Ratio2.6x
P/S RatioIs SRTS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SRTS income statement (TTM) | |
|---|---|
| Revenue | US$36.37m |
| Cost of Revenue | US$14.46m |
| Gross Profit | US$21.90m |
| Other Expenses | US$15.26m |
| Earnings | US$6.65m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.41 |
| Gross Margin | 60.23% |
| Net Profit Margin | 18.27% |
| Debt/Equity Ratio | 0% |
How did SRTS perform over the long term?
See historical performance and comparison